 | |
- close
- close
|
PR Newswire
Nov 23
Comment
SOUTH SAN FRANCISCO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that Dr. Ted W. Love and Dr. David C. U'Prichard have agreed to join the Anesiva board of directors following completion of the proposed
PR Newswire
Nov 9
Comment
SOUTH SAN FRANCISCO, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that on November 5, 2009, it received a letter from The NASDAQ Stock Market LLC ("Nasdaq") stating that the Nasdaq Hearing Panel has granted
PR Newswire
Oct 30
Comment
SOUTH SAN FRANCISCO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the Anesiva 2009 Annual Meeting of Stockholders will be held on December 3, 2009 at 9:00 a.m. PST at 400 Oyster Point, Suite 107A, South
PR Newswire
Sep 25
Comment
SOUTH SAN FRANCISCO, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that on September 24, 2009, it received a letter from The NASDAQ Stock Market ("Nasdaq"), dated September 17, 2009, stating that the minimum
FierceBiotech
Aug 5
Comment
Struggling pain management company Anesiva has been rescued from possible bankruptcy through a merger with Baltimore-based Arcion Therapeutics, a privately held company. The combined company will be known as Arcion Therapeutics. Arcion and...
Bloomberg
Jul 16
Comment
(Update1) A widely used method for reducing
pain and infections after heart bypass surgery increased the
rate of heart attacks and deaths after three years compared with
an older, conventional technique, researchers said.
Bloomberg
Jul 15
Comment
A widely used method for reducing
pain and infections after heart bypass surgery increased the
rate of heart attacks and deaths after three years compared with
an older, conventional technique, researchers said.
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
TOP CONTRIBUTORS
ANSV AT A GLANCE
Company Overview
Anesiva, Inc. was incorporated on January 19, 1999 in Delaware. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management. Their portfolio of products includes:
- Zingo™ (lidocaine hydrochloride monohydrate) powder intradermal injection system, which was approved by the Food and Drug Administration, the FDA, in August 2007 to reduce the pain associated with peripheral IV insertions or blood draws in children three to 18 years of age.
- Adlea™, a long-acting, site-specific, non-opioid analgesic, is being developed for moderate to severe pain, and has completed multiple Phase 2 trials in post-surgical, musculoskeletal and neuropathic pain and a Phase 3 trial in bunionectomy.
Zingo and Adlea are different drugs, each with its own mechanisms of action. Zingo is comprised of microcrystals of lidocaine delivered into the skin by compressed gas. Zingo employs a proprietary needle-free dispenser. Adlea is a novel non-opioid drug candidate that is a vanilloid receptor 1 agonist, or TRPV1 agonist, based on the compound capsaicin which provides analgesia for between two and three months. [1]
References
| ||||||
|
|
